Gilead Sciences (WBO:GILD) Future 3-5Y EPS without NRI Growth Rate : 22.87 (As of May. 19, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate is 22.87.

Competitive Comparison of Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Gilead Sciences (WBO:GILD) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Gilead Sciences Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).